| 1 | Name: | Dr. Carl June | |
| Institution: | University of Pennsylvania | ||
| Year Elected: | 2020 | ||
| Class: | 2. Biological Sciences | ||
| Subdivision: | 209. Neurobiology | ||
| Residency: | resident | ||
| Living? : | Living | ||
| Birth Date: | 1953 | ||
Carl June is a physician scientist and the Richard W. Vague Professor in Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania in the Departments of Medicine and Pathology and Laboratory Medicine. He is the director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and the Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. June graduated from the US Naval Academy and earned his medical degree in from the Baylor College of Medicine. He spent his fourth year of medical school at the World Health Organization in Geneva, Switzerland, studying immunology and malaria. June conducted postdoctoral research in transplantation biology at the Fred Hutchinson Cancer Center in Seattle from 1983 to 1986. June has published more than 500 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine, the American Academy of Arts and Sciences, the National Academy of Sciences, and has been named one of TIME Magazine’s 100 Most Influential People. He is the scientific founder of Xcyte Therapies Inc. and Tmunity Therapeutics. CTL019, the CAR T cell developed in the June laboratory was the first gene therapy to be approved by the US FDA in August 2017. The therapy developed by Dr. June’s team is now approved and marketed by Novartis in the US, Europe and Japan. Carl June was elected a member of the American Philosophical Society in 2020. | |||